.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Alendronate sodium - Generic Drug Details

« Back to Dashboard
Alendronate sodium is the generic ingredient in four branded drugs marketed by Dr Reddys Labs Ltd, Impax Labs Inc, Roxane, Sun Pharma Global, Aurobindo Pharma, Mylan, Mission Pharma, Jubilant Cadista, Austarpharma Llc, Merck And Co Inc, Cipla Ltd, Upsher-smith Labs, Merck, Apotex, Teva Pharms, and Watson Labs, and is included in nineteen NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

This ingredient has ninety-five patent family members in forty countries.

There are twenty-five drug master file entries for alendronate sodium. Thirty-one suppliers are listed for this compound.

Summary for Generic Name: alendronate sodium

Tradenames:4
Patents:5
Applicants:16
NDAs:19
Drug Master File Entries: see list25
Suppliers / Packaging: see list31
Therapeutic Class:Metabolic Bone Disease Agents
Formulation / Manufacturing:see details
Drug Prices:see low prices

Pharmacology for Ingredient: alendronate sodium

Ingredient-typeDiphosphonates
Drug ClassBisphosphonate
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs
ALENDRONATE SODIUM
alendronate sodium
TABLET;ORAL076984-002Aug 4, 2008RXNo► subscribe► subscribe
Austarpharma Llc
ALENDRONATE SODIUM
alendronate sodium
TABLET;ORAL090258-003Sep 24, 2009RXNo► subscribe► subscribe
Teva Pharms
ALENDRONATE SODIUM
alendronate sodium
TABLET;ORAL076184-002Aug 4, 2008DISCNNo► subscribe► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: alendronate sodium

These historical archives are available as an add-on to one-year subscriptions.
See the Subscription Options for more information.

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560-004Oct 20, 20005,681,590*PED► subscribe
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560-005Oct 20, 20005,681,590*PED► subscribe
Merck And Co Inc
FOSAMAX
alendronate sodium
TABLET;ORAL020560-001Sep 29, 19955,804,570► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: alendronate sodium

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,449,906Effervescent compositions comprising phosphonates and methods related thereto► subscribe
6,432,932 Method for inhibiting bone resorption► subscribe
6,333,316 Method for inhibiting bone resorption► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: alendronate sodium

Country Document Number Estimated Expiration
United Kingdom9819243► subscribe
Germany122006000009► subscribe
Luxembourg91222► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ALENDRONATE SODIUM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2007007Lithuania► subscribePRODUCT NAME: ACIDUM ALENDRONICUM NATRIUM, COLECALCIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001 2005 08 24 EU/1/05/310/002 2005 08 24 EU/1/05/310/003 2005 08 24 EU/1/05/310/004 2005 08 24 EU/1/05/310/00 20050824
2006 00005Denmark► subscribe
1175904/01Switzerland► subscribeFORMER OWNER: SCHERING CORPORATION, US
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc